US investor adds diagnostic company to portfolio:
This article was originally published in Clinica
Syngen Research, a US research company with proprietary diagnostic DNA amplification technologies, is to become part of the growing portfolio of Aethlon Medical. Aethlon, formerly Bishop Equities, is acquiring medical device technologies to commercialise on an international basis. Recently it gained Hemex, which has a blood purification technology device. In conjunction with a dialysis machine, the device, known as Hemopurifier, can remove targeted intoxicants such as iron, lead and aluminium from the blood. Future products in development include Hemopurifiers designed to remove certain viruses, plutonium and drug overdoses. Syngen and Aethlon are based in San Diego, California.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.